Oliver DÃ¶rr

List of Publications by Year
in descending order

80 papers	1,474 citations	361413 20 h-index	361022 35 g-index
83 all docs	83 docs citations	83 times ranked	2368 citing authors

#	Article	IF	Citations
1	Anatomical suitability and off-label use of contemporary transcatheter heart valves. International Journal of Cardiology, 2022, 350, 96-103.	1.7	5
2	Micro-dislodgement of a self-expanding transcatheter heart valve: Incidence, predictors, and outcomes. International Journal of Cardiology, 2022, 358, 77-82.	1.7	3
3	Fiveâ€year followâ€up of patients who underwent everolimusâ€eluting bioresorbable scaffold implantation. Catheterization and Cardiovascular Interventions, 2021, 97, 56-62.	1.7	0
4	CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. European Respiratory Journal, 2021, 57, 1901192.	6.7	15
5	Impact of the COVID-19 pandemic on cardiovascular mortality and catherization activity during the lockdown in central Germany: an observational study. Clinical Research in Cardiology, 2021, 110, 292-301.	3.3	63
6	Safety and effectiveness of coronary intravascular lithotripsy in eccentric calcified coronary lesions: a patient-level pooled analysis from the Disrupt CAD I and CAD II Studies. Clinical Research in Cardiology, 2021, 110, 228-236.	3.3	16
7	Aortic valve replacement in Germany in 2019. Clinical Research in Cardiology, 2021, 110, 460-465.	3.3	12
8	Fusion imaging guided implantation of a Tricento transcatheter heart valve for severe tricuspid regurgitation. Catheterization and Cardiovascular Interventions, 2021, 98, E780-E784.	1.7	4
9	Single versus double use of a suture-based closure device for transfemoral aortic valve implantation. International Journal of Cardiology, 2021, 331, 183-188.	1.7	2
10	Impact of Anesthesia Strategy and Valve Type on Clinical Outcomes After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2021, 77, 2204-2215.	2.8	28
11	Initial experience with a novel, modular, minimalistic approach for transfemoral aortic valve implantation. International Journal of Cardiology, 2021, 332, 54-59.	1.7	7
12	Feasibility of Coronary Access in Patients With Acute Coronary Syndrome and Previous TAVR. JACC: Cardiovascular Interventions, 2021, 14, 1578-1590.	2.9	18
13	Osteopontin and galectin-3 as biomarkers of maladaptive right ventricular remodelingÂin pulmonary hypertension. Biomarkers in Medicine, 2021, 15, 1021-1034.	1.4	6
14	Clinical presentation does not affect acute mechanical performance of the Novolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography. Postepy W Kardiologii Interwencyjnej, 2021, 17, 272-280.	0.2	1
15	Application and Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio in Patients with Ischemic and Non-Ischemic Cardiomyopathy. Diagnostics, 2021, 11, 2188.	2.6	4
16	Latest Developments in Robotic Percutaneous Coronary Intervention. Surgical Technology International, 2021, 38, 325-330.	0.2	0
17	Transvascular transcatheter aortic valve implantation in 2017. Clinical Research in Cardiology, 2020, 109, 303-314.	3.3	18
18	Lower mortality in an all-comers aortic stenosis population treated with TAVI in comparison to SAVR. Clinical Research in Cardiology, 2020, 109, 611-615.	3.3	10

#	Article	IF	Citations
19	Prognostic performance of the ESC SCORE and its German recalibrated versions in primary and secondary prevention. European Journal of Preventive Cardiology, 2020, 27, 2166-2169.	1.8	5
20	Fractional flow reserve and frequency of PCI in patients with coronary artery disease. Herz, 2020, 45, 752-758.	1.1	0
21	Who Is Afraid of CRP? Elevated Preoperative CRP Levels Might Attenuate the Increase in Inflammatory Parameters in Response to Lung Cancer Surgery. Journal of Clinical Medicine, 2020, 9, 3340.	2.4	7
22	General Versus Local Anesthesia With Conscious Sedation in Transcatheter Aortic Valve Implantation. Circulation, 2020, 142, 1437-1447.	1.6	81
23	Long-term follow-up and predictors of target lesion failure after implantation of everolimus-eluting bioresorbable scaffolds in real-world practice. International Journal of Cardiology, 2020, 312, 42-47.	1.7	4
24	Myeloid-related protein 8/14 and high-sensitivity cardiac troponin I to differentiate type 2 myocardial infarction. International Journal of Cardiology, 2020, 304, 144-147.	1.7	6
25	SPARCL1 as a biomarker of maladaptive right ventricular remodelling in pulmonary hypertension. Biomarkers, 2020, 25, 290-295.	1.9	11
26	IL10 Alters Peri-Collateral Macrophage Polarization and Hind-Limb Reperfusion in Mice after Femoral Artery Ligation. International Journal of Molecular Sciences, 2020, 21, 2821.	4.1	8
27	Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial. European Heart Journal, 2020, 41, 1890-1899.	2.2	159
28	Non-Invasive Approach for Evaluation of Pulmonary Hypertension Using Extracellular Vesicle-Associated Small Non-Coding RNA. Biomolecules, 2019, 9, 666.	4.0	30
29	First Experience with the New MitraClip NTR/XTR Device. Structural Heart, 2019, 3, 288-295.	0.6	2
30	Incidence and outcome of peri-procedural transcatheter heart valve embolization and migration: the TRAVEL registry (TranscatheteR HeArt Valve EmboLization and Migration). European Heart Journal, 2019, 40, 3156-3165.	2.2	92
31	Predictive value of preprocedural procalcitonin for short- and long-term mortality after transfemoral transcatheter aortic valve implantation. Heart and Vessels, 2019, 34, 1993-2001.	1.2	6
32	OCTâ€assessment of scaffold resorption: Analysis of strut intensity by a new resorption index for polyâ€lâ€lactic acid bioresorbable vascular scaffolds. Catheterization and Cardiovascular Interventions, 2019, 94, 928-935.	1.7	0
33	Effect of Plaque Composition, Morphology, and Burden on DESolve Novolimus-Eluting Bioresorbable Vascular Scaffold Expansion and Eccentricity â€" An Optical Coherence Tomography Analysis. Cardiovascular Revascularization Medicine, 2019, 20, 480-484.	0.8	4
34	Anti-citrullinated protein antibodies are not associated with extent of disease or prognosis in patients with coronary artery disease. Clinical Chemistry and Laboratory Medicine, 2019, 57, e159-e161.	2.3	0
35	A multicenter postâ€marketing evaluation of the Elixir DESolve^{Â®} Novolimusâ€eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study. Catheterization and Cardiovascular Interventions, 2018, 92, 1021-1027.	1.7	21
36	Specific biomarkers of myocardial inflammation and remodeling processes as predictors of mortality in highâ€risk patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 481-487.	1.8	11

#	Article	IF	Citations
37	Outcome of thrombus aspiration in STEMI patients: a propensity score-adjusted study. Journal of Thrombosis and Thrombolysis, 2018, 45, 240-249.	2.1	2
38	Outcome after transvascular transcatheter aortic valve implantation in 2016. European Heart Journal, 2018, 39, 667-675.	2.2	61
39	Pacemaker implantation after TAVI: predictors of AV block persistence. Clinical Research in Cardiology, 2018, 107, 60-69.	3.3	71
40	Evaluation of cystatin C and neutrophil gelatinaseâ€associated lipocalin as predictors of mortality in patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 1474-1479.	1.8	4
41	Galectinâ€3 and ST2 as predictors of therapeutic success in highâ€risk patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 1164-1169.	1.8	6
42	Biomarker response and therapy prediction in renal denervation therapy â€“ the role of MR-proadrenomedullin in a multicenter approach. Biomarkers, 2017, 22, 225-231.	1.9	5
43	Trends in aortic valve replacement in Germany in 2015: transcatheter versus isolated surgical aortic valve repair. Clinical Research in Cardiology, 2017, 106, 411-419.	3.3	52
44	Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the TreatmentÂof Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 477-485.	2.9	12
45	Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100. International Journal of Cardiology, 2017, 246, 74-79.	1.7	10
46	A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives. International Journal of Cardiology, 2017, 227, 127-133.	1.7	23
47	Identification of Periprocedural Myocardial Infarction Using a High-Sensitivity Troponin I Assay in Patients Who Underwent Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 120, 1180-1186.	1.6	9
48	Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects. Clinical Research in Cardiology, 2017, 106, 271-279.	3.3	6
49	Release kinetics of high-sensitivity cardiac troponins I and T and troponin T upstream open reading frame peptide (TnTuORF) in clinically induced acute myocardial infarction. Biomarkers, 2017, 22, 304-310.	1.9	10
50	Bioresorbable scaffold implantation in patients with indication for oral anticoagulation: A propensity matched analysis. International Journal of Cardiology, 2017, 231, 73-77.	1.7	0
51	Longâ€term verification of functional and structural renal damage after renal sympathetic denervation. Catheterization and Cardiovascular Interventions, 2016, 87, 1298-1303.	1.7	3
52	Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1144-1151.	0.6	1
53	Rescue baroreflex activation therapy after Stanford B aortic dissection due to therapy-refractory hypertension. Journal of the American Society of Hypertension, 2016, 10, 490-492.	2.3	7
54	Plasma microRNA-21 for the early prediction of acute kidney injury in patients undergoing major cardiac surgery. Nephrology Dialysis Transplantation, 2016, 31, 760-766.	0.7	36

#	Article	IF	Citations
55	Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions â€" Implications from early clinical experience during daily practice. Cardiovascular Revascularization Medicine, 2016, 17, 313-317.	0.8	6
56	Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clinical Research in Cardiology, 2016, 105, 755-762.	3.3	21
57	Barostim Implantation with Ipsilateral Carotid Endarterectomy as a One-Stage Procedure. Annals of Vascular Surgery, 2016, 36, 295.e9-295.e11.	0.9	2
58	N-terminal fragment of cardiac myosin binding protein-C triggers pro-inflammatory responses in vitro. Journal of Molecular and Cellular Cardiology, 2016, 99, 47-56.	1.9	20
59	A new novolimus-eluting bioresorbable scaffold for large coronary arteries: an OCT study of acute mechanical performance. International Journal of Cardiology, 2016, 220, 706-710.	1.7	7
60	Implantation of everolimusâ€eluting bioresorbable scaffolds in a diabetic allâ€comers population. Catheterization and Cardiovascular Interventions, 2015, 86, 975-981.	1.7	8
61	Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation. Clinical Research in Cardiology, 2015, 104, 1064-1071.	3.3	21
62	Brain-Derived Neurotrophic Factor as aÂMarker for Immediate Assessment of the SuccessÂof Renal Sympathetic Denervation. Journal of the American College of Cardiology, 2015, 65, 1151-1153.	2.8	19
63	First-in-Man Coronary Sinus Lead Stabilization Using a Bioresorbable Vascular Scaffold System. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1518-1519.	4.8	0
64	Impact of the learning curve on procedural results and acute outcome after percutaneous coronary interventions with everolimus-eluting bioresorbable scaffolds in an all-comers population. Cardiovascular Revascularization Medicine, 2015, 16, 455-460.	0.8	17
65	Release Kinetics of Inflammatory Biomarkers in a Clinical Model of Acute Myocardial Infarction. Circulation Research, 2015, 116, 867-875.	4.5	51
66	Influence of Renal Sympathetic Denervation on Cardiac Extracellular Matrix Turnover and Cardiac Fibrosis. American Journal of Hypertension, 2015, 28, 1285-1292.	2.0	15
67	New potential diagnostic biomarkers for pulmonary hypertension. European Respiratory Journal, 2015, 46, 1390-1396.	6.7	32
68	Reference Values and Release Kinetics of B-Type Natriuretic Peptide Signal Peptide in Patients with Acute Myocardial Infarction. Clinical Chemistry, 2015, 61, 1532-1539.	3.2	7
69	Bioresorbable scaffolds for the treatment of in-stent restenosis. Heart and Vessels, 2015, 30, 265-269.	1.2	7
70	High-sensitivity cardiac troponin T and copeptin assays to improve diagnostic accuracy of exercise stress test in patients with suspected coronary artery disease. European Journal of Preventive Cardiology, 2015, 22, 684-692.	1.8	16
71	Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension. Clinical Research in Cardiology, 2015, 104, 175-184.	3.3	37
72	Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion. International Journal of Cardiology, 2015, 179, 90-94.	1.7	26

#	Article	IF	Citations
73	Release kinetics of N-terminal pro-B-type natriuretic peptide in a clinical model of acute myocardial infarction. Clinica Chimica Acta, 2014, 429, 34-37.	1.1	12
74	Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clinical Research in Cardiology, 2014, 103, 141-148.	3.3	49
75	Soluble fms-Like Tyrosine Kinase-1 and Endothelial Adhesion Molecules (Intercellular Cell Adhesion) Tj ETQq1 1 0.784314 rgBT /Overlock Reduction After Renal Sympathetic Denervation. Hypertension, 2014, 63, 984-990.	2.7	50
76	Influence of Renal Sympathetic Denervation on Quality of Life. Journal of Interventional Cardiology, 2013, 26, 536-541.	1.2	6
77	Renal Sympathetic Denervation Does Not Aggravate Functional or Structural Renal Damage. Journal of the American College of Cardiology, 2013, 61, 479-480.	2.8	23
78	Neutrophil gelatinase-associated lipocalin (NGAL) for the early detection of cardiac surgery associated acute kidney injury. Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 392-399.	1.2	40
79	Transapical Coronary Artery Intervention. Circulation: Cardiovascular Interventions, 2012, 5, 446-447.	3.9	1
80	Latest Developments in Robotic Percutaneous Coronary Intervention. Surgical Technology International, 0, , .	0.2	2